Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semaglutide

Ozempic, Rybelsus, Wegovy

Quick Stats
Studies 78
Trials 100
Score 3
2025 pubmed

Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report.

Liekens. Lisa L; Kaïret. Koen K; Elst. Elisabeth F EF

Key Findings

  • Semaglutide use was linked to worsening of atypical anorexia nervosa in an adolescent.
  • The patient experienced bradycardia and pericardial effusion, serious cardiac complications.
  • Stopping semaglutide did not immediately halt weight loss, and anxiety about weight gain persisted.

Practical Outcomes

  • If you are considering semaglutide for weight control, avoid it if you have a history of eating disorders, anxiety about weight, or are under 18. Monitor mental health closely and have a clinician ready to intervene. Use the drug only under strict medical supervision with regular follow‑up for psychological side effects.

Summary

A teenage girl with atypical anorexia nervosa took semaglutide, a weight‑loss drug, and her eating disorder got worse, leading to serious heart problems and a hospital stay. Even after stopping the drug, she kept losing weight and later had a panic attack when she gained a little weight. The case shows that semaglutide can worsen mental health issues in people already prone to eating disorders, especially young people.

Abstract

Anorexia nervosa is characterised by the fear of gaining weight and a disrupted relationship with food but atypical if the body mass index is within normal limits. Semaglutide is a glucagon-like peptide-1 receptor agonist, indicated in patients with diabetes type 2 and obesity. An adolescent girl was diagnosed with atypical anorexia nervosa. She had a fear of gaining weight, she increased her exercise and decreased her caloric intake. The adolescent was admitted to the paediatric ward with bradycardia and pericardial effusion. During her hospital stay she admitted to having used semaglutide. Semaglutide was prescribed by her general practitioner because she was previously on the verge of being overweight with weight-related dysphoria. After 3 months she stopped using semaglutide, she kept losing weight. The adolescent girl went back to her normal life but after a panic attack caused by gaining 1 kg, she was admitted to an eating disorder ward. Semaglutide can affect mental health in patients who are prone to mental disorders. The importance of restrictively prescribing semaglutide for the right indication with caution and strict follow up is emphasised.

Study Information

Provider

pubmed

Year

2025

Date

2025-12-01T00:00:00.000Z

DOI

10.1192/bjo.2025.10909

References

29